Cargando…
Endocan removal during continuous renal replacement therapy: does it affect the reliability of this biomarker?
Autores principales: | Honore, Patrick M., De Bels, David, Attou, Rachid, Redant, Sebastien, Gallerani, Andrea, Kashani, Kianoush |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6532174/ https://www.ncbi.nlm.nih.gov/pubmed/31118066 http://dx.doi.org/10.1186/s13054-019-2469-7 |
Ejemplares similares
-
Adsorption and caspofungin dosing during continuous renal replacement therapy
por: Honore, Patrick M., et al.
Publicado: (2019) -
The challenge of removal of sepsis markers by continuous hemofiltration
por: Honore, Patrick M., et al.
Publicado: (2019) -
Treatment of influenza virus-related critical illness during continuous renal replacement therapy: take caution with dosing
por: Honore, Patrick M., et al.
Publicado: (2020) -
No dose adjustment of tigecycline is necessary during continuous renal replacement therapy: we are not sure
por: Honore, Patrick M., et al.
Publicado: (2020) -
Vitamin C Dosing During Continuous Renal Replacement Therapy: The Last Word is Not Said!
por: Honore, Patrick M., et al.
Publicado: (2019)